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median total interval and median treatment interval as 
cutoff points to divide patients. Univariable and 
multivariable Cox proportional hazard model was used to 
evaluate overallsurvival (OS).  
 
 
 
Results: At a median follow up of 37 months, the 3-year OS 
for the entire cohort was 63%. Median total interval and 
treatment interval were of 98 days and 29 days, respectively. 
Patients with longer total interval were more likely to be 
patients with a low comorbidity grade (ACE-27 grade 0-1). On 
multivariable analysis a longer total interval was associated 
with a reduced risk of dying (hazard ratio 0.37, 95% CI 0.13 – 
1,01; p = 0.05). No association of longer treatment interval 
with OS was noted on univariable and multivariable analysis. 
Longer treatment interval resulted associated with the use of 
PET for staging (p = 0.13), and with the use of CCRT for 
treatment (p = 0.05). In the subgroup analysis by treatment 
modality, no difference in OS according to treatment interval 
was noted. 
 
Conclusion: In HNSCC patients with stage III-IV at diagnosis, a 
reduction of total interval and of treatment delay does not 
ameliorate survival. Development of fast track referral 
strategies should be aimed at increasing the ratio of stage I-II 
patients. 
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Purpose or Objective: In head and neck cancer absolute 
improvements in locoregional control rate and overall 
survival rate are achieved when radiotherapy is accelerated. 
Concurrent chemotherapy also have been used to improve 
outcomes at the cost of increased toxicity. The use of IMRT 
for head and neck cancer has been associated with reduced 
acute toxicity. Clinical experience with accelerated IMRT-SIB 
with concurrent chemotherapy for advanced oropharyngeal 
squamous cell carcinoma (LAOC), however, is limited. 
Objective of our study is to evaluate efficacy and toxicity of 
an accelerated hypofractionated SIB-IMRT with Tomotherapy 
and concurrent chemotherapy in LAOC. 
 
Material and Methods: Between July 2009 and February 
2014, 59 consecutive patients with LAOC received 
accelerated hypofractionated radiotherapy with tomotherapy 
and concurrent chemotherapy. The disease was stage III in 8% 
and stage IVa in 92% of patients. Prescribed doses to primary 
tumor and involved nodes was 66 Gy at 2,2 Gy/fraction, high 
risk and low risk nodes received simultaneously 60 Gy and 54 
Gy at 2,0 Gy and 1,8 Gy/fraction, over 6 weeks. Acute 
toxicity was scored according to RTOG and late toxicity 
according to CTCAE-4 criteria. The disease free survival 
(DFS), local disease free survival (local-DFS), metastasis free 
survival (MFS) and overall survival were calculated using the 
Kaplan-Meier method. 
 
Results: With median follow-up of 38 months (range 14-70) 
the estimated 3-years local-DFS rate, MFS, DFS and OS were 
88%±0.04SE, 91%±0.04SE, 82%±0.05SE, and 83%±0.04SE, 
respectively. The complete response rate was 88%. All the 
patients completed the radiotherapy; the median treatment 
duration was 43 days, six patients have temporarily 
discontinued treatment (median: 5 days) because of toxicity. 
No grade 4 acute toxicitiy was observed, maximal acute 
toxicities were G3: mucosa 31%, skin 15%, dysphagia 24%, 
leukopenia 5%. Maximal late toxicities were: xerostomia G2 
36%, mucosa G2 23%, skin G2 12%, laryngeal G2 17%, 
dysphagia G2 14%, osteoradionecrosis 3%, trismus 9%. 
 
Conclusion: This analysis shows that a moderatly accelerated 
hypofractionated IMRT-SIB in tomotherapy and concurrent 
chemotherapy achieved high tumor local control and 
acceptable toxicity compared with previous 
chemoradiotherapy treatment with standard fractionation. 
Based on these results we elaborate a randomized clinical 
trial with a more hypofractionated regimen in order to obtain 
a better local control without increasing toxicity. 
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Purpose or Objective: Overall treatment time (OTT) is an 
important factor in head and neck radiotherapy of squamous-
cell carcinoma, the authors investigate its role in a 
nasopharyngeal carcinoma (NPC) population. 
 
Material and Methods: We reviewed 109 patients charts with 
NPC. Pathological, clinical and dosimetric data were 
retrieved. All patients received concomitant chemo-radiation 
(CCRT) with IMRT-SIB with 69.96Gy to GTVs, 59.4 and 54Gy to 
CTVs in 33 fractions (RTOG0615). Cisplatin-based 
chemotherapy (CT) was prescribed as per Intergoup 0099. 
OTT was recorded from the first day of radiation through the 
last day of CCRT regardless adjuvant CT. Per protocol 
treatment was defined as OTT < 7 weeks. Any interruption 
was recorded as well its length and cause. Kaplan-Meier 
curves were created by SPSS (IBM Statistics), log-rank test 
was applied to detect differences and Cox regression model 
was adjusted to compare variables. 
 
Results: From 109 patients, median age was 53; 74% male; 
71% were WHO grade III; 43% T1; 14% T2; 18% T3, 25% T4; 17% 
N0; 17% N1; 39% N2; 27% N3. With a median follow up of 22 
months, 2-year local control was 95,9%, freedom from 
metastases was 88% and overall survival was 79,8%. 9 
